CN107936008A - 氘代化合物及其医药用途 - Google Patents
氘代化合物及其医药用途 Download PDFInfo
- Publication number
- CN107936008A CN107936008A CN201610890151.8A CN201610890151A CN107936008A CN 107936008 A CN107936008 A CN 107936008A CN 201610890151 A CN201610890151 A CN 201610890151A CN 107936008 A CN107936008 A CN 107936008A
- Authority
- CN
- China
- Prior art keywords
- caused
- compound
- pharmaceutically acceptable
- acceptable salt
- habituation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (6)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610890151.8A CN107936008B (zh) | 2016-10-13 | 2016-10-13 | 氘代化合物及其医药用途 |
JP2019541837A JP7050336B2 (ja) | 2016-10-13 | 2017-09-22 | 重水素化化合物及びその医薬的用途 |
PCT/CN2017/000607 WO2018068429A1 (zh) | 2016-10-13 | 2017-09-22 | 左旋四氢帕马汀氘代衍生物及其医药用途 |
EP17861072.1A EP3517537B1 (en) | 2016-10-13 | 2017-09-22 | Deuterated derivative of l-tetrahydropalmatine and medical use thereof |
US16/383,307 US10617679B2 (en) | 2016-10-13 | 2019-04-12 | Deuterated compounds and medical uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610890151.8A CN107936008B (zh) | 2016-10-13 | 2016-10-13 | 氘代化合物及其医药用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107936008A true CN107936008A (zh) | 2018-04-20 |
CN107936008B CN107936008B (zh) | 2022-06-14 |
Family
ID=61905096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610890151.8A Active CN107936008B (zh) | 2016-10-13 | 2016-10-13 | 氘代化合物及其医药用途 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10617679B2 (zh) |
EP (1) | EP3517537B1 (zh) |
JP (1) | JP7050336B2 (zh) |
CN (1) | CN107936008B (zh) |
WO (1) | WO2018068429A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111184719A (zh) * | 2020-01-17 | 2020-05-22 | 上海交通大学 | 一种多巴胺受体拮抗剂及其用途 |
CN113354634A (zh) * | 2020-03-06 | 2021-09-07 | 中国科学院化学研究所 | 化合物及含有其的药物组合物和在治疗脑瘤中的用途 |
CN115260185A (zh) * | 2022-08-02 | 2022-11-01 | 杨征 | 金黄紫堇碱和千金藤啶碱的氘代衍生物及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5019788A (zh) * | 1973-06-25 | 1975-03-01 | ||
CN1483407A (zh) * | 2002-09-18 | 2004-03-24 | 中国人民解放军军事医学科学院毒物药 | 用于镇痛和戒毒的含罗通定的药物组合物 |
KR20100064512A (ko) * | 2008-12-05 | 2010-06-15 | 대한민국 (식품의약품안전청장) | L-thp를 유효성분으로 포함하는 약물남용 치료제 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2896678T3 (es) * | 2008-09-18 | 2022-02-25 | Auspex Pharmaceuticals Inc | Derivados deuterados de benzoquinolina como inhibidores del transportador de monoamina vesicular 2 |
CN103520010A (zh) * | 2013-10-18 | 2014-01-22 | 柳州两面针股份有限公司 | 延胡索乙素与柚皮苷在制备口腔护理品中的应用 |
-
2016
- 2016-10-13 CN CN201610890151.8A patent/CN107936008B/zh active Active
-
2017
- 2017-09-22 JP JP2019541837A patent/JP7050336B2/ja active Active
- 2017-09-22 EP EP17861072.1A patent/EP3517537B1/en active Active
- 2017-09-22 WO PCT/CN2017/000607 patent/WO2018068429A1/zh unknown
-
2019
- 2019-04-12 US US16/383,307 patent/US10617679B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5019788A (zh) * | 1973-06-25 | 1975-03-01 | ||
CN1483407A (zh) * | 2002-09-18 | 2004-03-24 | 中国人民解放军军事医学科学院毒物药 | 用于镇痛和戒毒的含罗通定的药物组合物 |
KR20100064512A (ko) * | 2008-12-05 | 2010-06-15 | 대한민국 (식품의약품안전청장) | L-thp를 유효성분으로 포함하는 약물남용 치료제 |
Non-Patent Citations (2)
Title |
---|
卢咏泉 等: "罗通定治疗海洛因依赖者稽延性戒断症状的临床疗效观察", 《中国药物滥用防治杂志》 * |
章辛 等: "2H和3H标记四氢小檗碱的制备", 《核技术》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111184719A (zh) * | 2020-01-17 | 2020-05-22 | 上海交通大学 | 一种多巴胺受体拮抗剂及其用途 |
CN111184719B (zh) * | 2020-01-17 | 2023-02-28 | 上海交通大学 | 一种多巴胺受体拮抗剂及其用途 |
CN113354634A (zh) * | 2020-03-06 | 2021-09-07 | 中国科学院化学研究所 | 化合物及含有其的药物组合物和在治疗脑瘤中的用途 |
CN115260185A (zh) * | 2022-08-02 | 2022-11-01 | 杨征 | 金黄紫堇碱和千金藤啶碱的氘代衍生物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
EP3517537A4 (en) | 2020-05-27 |
JP2019531353A (ja) | 2019-10-31 |
CN107936008B (zh) | 2022-06-14 |
EP3517537B1 (en) | 2023-09-13 |
US20190240204A1 (en) | 2019-08-08 |
WO2018068429A1 (zh) | 2018-04-19 |
US10617679B2 (en) | 2020-04-14 |
JP7050336B2 (ja) | 2022-04-08 |
EP3517537A1 (en) | 2019-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105579034B (zh) | 一种gabaa受体增强剂用于制备镇静麻醉的药物中的用途 | |
CN103221414B (zh) | 苯并二氮杂*衍生物的托西酸盐及其多晶型、它们的制备方法和用途 | |
CN106866733B (zh) | 左旋美普他酚前药及其制备方法和用途 | |
CN100545164C (zh) | 斑蝥酸钠的制备工艺 | |
CN107936008A (zh) | 氘代化合物及其医药用途 | |
CN102344408B (zh) | 双效麻醉药物 | |
CN102140079B (zh) | 新乌碱及其制备方法和以该化合物为活性成分的药物组合物及用途 | |
CN114948953A (zh) | 一种杂原子取代芳香类化合物及其盐的用途 | |
CN107488162A (zh) | 一类双环醇类衍生物及其制备和应用 | |
CN110343033A (zh) | 厚朴酚系列衍生物及其制备方法和用途 | |
CN111217749A (zh) | 氘代喷他佐辛及制备方法、医药组合物和用途 | |
CN105125481B (zh) | 一种马来酸甲麦角新碱注射液及其制备方法 | |
CN102617584B (zh) | 一种盐酸伊立替康化合物及其药物组合物 | |
CN102389434B (zh) | 一种治疗缺血性脑血管病的药物组合物及其制备方法 | |
WO2008049317A1 (en) | Biphenyl acetate, preparation and uses thereof | |
CN104086531B (zh) | 一种埃索美拉唑钠化合物及其药物组合物 | |
CN113024557A (zh) | 一种Peganumine A生物碱结构简化物及其应用 | |
CN100425603C (zh) | 一种抗脑缺血、心肌缺血并改善记忆功能的化合物及其制备方法和制备药物的应用 | |
CN103373959A (zh) | 顺式苄基异喹啉类化合物的制备方法及其用途 | |
KR20080014767A (ko) | 하이드로모르폰 다형태 | |
CN104478798B (zh) | N‑氨基烷基磺酰基‑3‑吡啶甲酰胺衍生物及其在制备治疗心脑血管病药物中的应用 | |
CN114380834B (zh) | 一种酮咯酸衍生物及制备方法和应用 | |
CN1039198C (zh) | 一种二萜生物碱的制备方法 | |
CN103193857A (zh) | 止泻木生物碱衍生物及其用途 | |
CN105503888A (zh) | 一种盐酸纳洛酮晶型化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190513 Address after: 101503 Room 223-2131, 142 Huasheng Road, Beizhuang Village, Beizhuang Town, Miyun District, Beijing Applicant after: Jinglu Latitude Information Consulting (Beijing) Co., Ltd. Address before: 225312 Room 707, Building D, Phase II, New Drug Creation Base, No. 1 Yaocheng Avenue, Taizhou City, Taizhou City, Jiangsu Province Applicant before: Taizhou Huayuan Medicine Technology Co., Ltd. |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200707 Address after: Room 1412, building D, phase II, new drug development base, No.1 Yaocheng Avenue, Taizhou City, Jiangsu Province (east side of Chuangye road and north side of Yuannan Road) Applicant after: JINGLUWEIDAI INFORMATION CONSULTING SERVICE (BEIJING) Co.,Ltd. Address before: 101503 Room 223-2131, 142 Huasheng Road, Beizhuang Village, Beizhuang Town, Miyun District, Beijing Applicant before: Jinglu Latitude Information Consulting (Beijing) Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |